Xilis’ proprietary MicroOrganoSphereTM (MOS) technology represents a new standard in patient-derived micro-tumor production. From each patient, MOSTM retains unique patient tissue structure, genetic alterations, gene expression, immune microenvironment and histopathology. Overcoming major limitations of widely used, yet limited, models including xenografts and organoids, MOSTM offers unprecedented speed, scalability, and predictivity in a small-scale model, opening up tremendous opportunities using patient-derived micro-tumors in drug development and discovery as well as drug prioritization assays for patients.
Efficient • Scalable • Consistent
Xilis’ proprietary hardware is a highly adaptable microscale encapsulation system for the manipulation and study of complex and biologically-relevant 3D models of tissue. By combining microfluidics, extracellular-matrices, robotics, protocols, assays, and expertise, the MOSTM technology offers a rapid, automated, scalable and reproducible solution that is uniquely suited for the advancement of translational research.
Capturing the Entire Patient Tumor
Xilis’ MOS technology recapitulates the complexity and diversity of a patient’s primary tissue. The figure shows the cluster distribution of gene expression across all cell populations in tissue (left) and from MOS (right). When superimposed, the two graphs are indistinguishable. This demonstrates that MOS maintains the same heterogeneous tumor microenvironment found in primary tissue samples. Therefore, MOS accurately represents a patient’s complete disease state and is a predictive tumor model suitable for measuring cell viability and drug response, and most importantly, the prioritization of patient care.
MOS technology recapitulates the complexity and diversity of a patient’s primary tissue. This data has been presented at ASCO 2021. MOS can accurately represent a patient’s complete disease state and is a predictive tumor model suitable for measuring cell viability and drug response, and more importantly, the prioritization of patient care.
The MOSTM technology overcomes issues of reproducibility with conventional organoid technologies for evaluating drug response. As shown in the image, we can generate reproducible data that allows for better consistency, accuracy and efficiency through automated procedures that reduce hands-on time for lab personnel.
Xilis’ Machine Learning Tools
Xilis has developed AI imaging analysis tools to automatically track and accurately measure each MOSTM over time for treatment response. This enables rapid diagnosis from biopsies for precision oncology and high-throughput screening for drug discovery.
By predicting drug response within 14 days, the Xilis Precision Oncology Platform and Xilis Response Score allow clinicians to make timely decisions and prioritize individualized treatment strategies for each patient. To learn more, visit our Precision Oncology section.
Drug Development Capabilities
Xilis’ technology enables drug developers to scale and streamline all phases of preclinical and clinical development, resulting in more efficient use of resources by our partners. Xilis has been able to successfully capture the complex environment of cancer and healthy tissues, including breast, lung and liver, enabling the ex-vivo modeling of entirely new classes of drugs, including immuno-oncology. Xilis is currently collaborating with key academic and pharma partners. To learn more, visit our Drug Development section.